Johnson & Johnson

NYSE:JNJ   3:59:57 PM EDT
161.28
+1.17 (+0.73%)
4:37:52 PM EDT: $161.21 -0.07 (-0.04%)
Mergers / Acquisitions

Janssen Acquires Rights To Novel Gene Therapy, Pioneering Treatment Solutions For Late-Stage Age-Related Macular Degeneration

Published: 12/02/2020 13:25 GMT
Johnson & Johnson (JNJ) - Janssen Acquires Rights to Novel Gene Therapy, Pioneering Treatment Solutions for Late-stage Age-related Macular Degeneration.
Janssen Pharmaceuticals Inc- Financial Terms of Transaction With Hemera Biosciences Are Not Being Disclosed.